Advertisement

Related Videos

Welcome and Introduction to Vi3C

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Peter Clark, MA, MD, FRCP: A Payer Perspective

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Dec
08
Today In Oncology
Trastuzumab Duocarmazine in Previously Treated HER2-Positive Metastatic Breast Cancer
Impact of Prevention and Screening on Mortality From Five Common Cancers
Cancer Risk Associated With Use of Disease-Modifying Antirheumatic Drugs
Novel Oncolytic Immunotherapy Yields Durable Responses in High-Risk Bladder Cancer
Novel Immunotherapy May Offer Benefit in Early Clinical Trial for Breast Cancer
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Conexiant Oncology Logo